A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.Published in:2017By:Bendell, Johanna C;Javle, Milind;Bekaii-Saab, Tanios S;Finn, Richard S;Wainberg, Zev A;Laheru, Daniel A;Weekes, Colin D;Tan, Benjamin R;Khan, Gazala N;Zalupski, Mark M;Infante, Jeffrey R;Jones, Suzanne;Papadopoulos, Kyriakos P;Tolcher, Anthony W;Chavira, Renae E;Christy-Bittel, Janna L;Barrett, Emma;Patnaik, AmitaPublication type:journal article
